• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

382.27 -4.19 (-1.08%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 359,351
Open 378.06
Bid (Size) 373.00 (520)
Ask (Size) 390.18 (200)
Prev. Close 386.46
Today's Range 375.52 - 384.81
52wk Range 253.95 - 388.66
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
October 22, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
October 19, 2026
From BeOne Medicines Ltd.
Via Business Wire

Performance

52-Week Range 1.6% below 52-week high
382.27
253.9552W Low 388.6652W High
1 Week 1.6% below 1-week high
367.301W Low 388.661W High

BeOne Medicines Ltd. - American Depositary Shares (ONC) traded between $253.95 and $388.66 over the past 52 weeks and last traded at $382.27, 1.6% below its 52-week high. Over the past week it ranged between $367.30 and $388.66.

Past 12 Months
+3.6%
+3.9%
+17.0%
+27.5%
+22.9%
+21.9%
1W +$13.21
1M +$14.19
3M +$55.50
6M +$82.46
YTD +$71.25
1Y +$68.73

ONC was +21.9% over the past year, +27.5% over six months, +22.9% year to date, +3.6% in the last week.

12 Months vs Market
ONC
+21.9%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months ONC returned +21.9% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.93× 3-mo avg
Today 359,351 3-mo avg 385.5K
1W
412.0K
1M
389.8K
3M
385.5K
6M
342.7K
YTD
311.8K
1Y
305.4K

ONC most recently traded 359,351 shares against a 3-month average daily volume of 385.5K.

More News

Read More
News headline image
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
September 01, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
August 31, 2026
From BeOne Medicines, Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
August 31, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
August 25, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
August 18, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
News headline image
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
August 05, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
July 23, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗
July 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
July 17, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
June 30, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
June 12, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
June 11, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗
June 02, 2026
Via MarketBeat
News headline image
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
June 01, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
May 29, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
May 27, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
May 21, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
May 20, 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
May 16, 2026
Via The Motley Fool

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?
Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.
What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?
BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?
The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
What is the current price of BeOne Medicines Ltd. - American Depositary Shares?
The current price of BeOne Medicines Ltd. - American Depositary Shares is 382.27
When was BeOne Medicines Ltd. - American Depositary Shares last traded?
The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 10/22/26 04:00 PM ET
What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?
The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 462.95B
How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?
BeOne Medicines Ltd. - American Depositary Shares has 463B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap